Serum PRO-C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort

doi:10.1111/liv.15878

科研成果详情

题名	Serum PRO-C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort
作者	Tang, Liang-Jie 1,2; Sun, Dan-Qin 3,4; Song, Sherlot Juan 5,6; Yip, Terry Cheuk-Fung 5,6; Wong, Grace Lai-Hung 5,6; Zhu, Pei-Wu7; Chen, Sui-Dan8; Karsdal, Morten 9; Leeming, Diana Julie 9; Jiang, Pei 10; Wang, Cong 10; Chen, Qiang 2,11; Byrne, Christopher D.12; Targher, Giovanni 13,14; Eslam, Mohammed 15,16; George, Jacob 15,16; Wong, Vincent Wai-Sun 5,6; Zheng, Ming-Hua1,17,18
发表日期	2024-05
发表期刊	LIVER INTERNATIONAL 影响因子和分区
语种	英语
原始文献类型	Article ; Early Access
关键词	chronic kidney disease liver fibrosis metabolic dysfunction-associated fatty liver disease metabolic dysfunction-associated steatotic liver disease N-terminal propeptide of type 3 collagen risk prediction
其他关键词	FATTY LIVER-DISEASE ; NAFLD ; PATHOGENESIS ; DIAGNOSIS ; SYSTEM
摘要	Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is an emerging risk factor for chronic kidney disease (CKD). N-terminal propeptide of collagen type 3 (PRO-C3) is a biomarker of advanced fibrosis in MAFLD and PRO-C3 may be involved in renal fibrosis. We aimed to use PRO-C3 measurements to generate a new algorithmic score to test the prediction of MAFLD with chronic kidney disease (MAFLD-CKD). Methods: A derivation and independent validation cohort of 750 and 129 Asian patients with biopsy-confirmed MAFLD were included. Serum PRO-C3 concentration was measured and regression analyses were performed to examine associations with MAFLD-CKD. A derivative algorithm for MAFLD-CKD risk prediction was evaluated with receiver operator characteristic (ROC) curve analysis. Results: The study included two Asian cohorts (n = 180 with MAFLD-CKD; mean-eGFR: 94.93 mL/min/1.73 m2; median-urinary albumin-to-creatinine ratio: 6.58 mg/mmol). PRO-C3 was associated with the severity of MAFLD-CKD and independently associated with MAFLD-CKD (adjusted odds ratio = 1.16, 95% confidence interval [CI]: 1.08-1.23, p < .001). A new non-invasive score (termed PERIOD) including PRO-C3 efficiently predicted MAFLD-CKD (AUROC = .842, 95% CI: .805-.875). Accuracy, specificity and negative predictive values were 80.2%, 85.1% and 88.4%, respectively. In the validation cohort, the PERIOD score had good diagnostic performance (AUROC = .807, 95% CI: .691-.893) with similar results in all patient subgroups. In the MAFLD-CKD subgroup, the accuracy for identifying advanced fibrosis was further improved by combining the PRO-C3-based ADAPT with the Agile 3+ scores (AUROC = .90, 95% CI: .836-.964). Conclusions: The PERIOD score is helpful for accurately predicting the risk of MAFLD-CKD. PRO-C3 can also be used to assess liver fibrosis in people with MAFLD-CKD.
资助项目	National Health and Medical Research Council of Australia
出版者	WILEY
ISSN	1478-3223
EISSN	1478-3231
卷号	44 期号:5 页码:1129-1141
DOI	10.1111/liv.15878
页数	13
WOS类目	Gastroenterology & Hepatology
WOS研究方向	Gastroenterology & Hepatology
WOS记录号	WOS:001176362200001
收录类别	SCIE ; PUBMED ; SCOPUS
在线发表日期	2024-03
URL	查看原文
PubMed ID	38426611
SCOPUSEID	2-s2.0-85186233895
通讯作者地址	[Zheng, Ming-Hua]MAFLD Research Center,Department of Hepatology,The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China ; [Wong, Vincent Wai-Sun]Department of Medicine and Therapeutics,The Chinese University of Hong Kong,Hong Kong
Scopus学科分类	Hepatology
TOP期刊	TOP期刊
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/209320
专题	附属第一医院温州医科大学附属第一医院_感染内科
通讯作者	Wong, Vincent Wai-Sun; Zheng, Ming-Hua
作者单位	1.MAFLD Research Center,Department of Hepatology,The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China; 2.Cancer Center,Faculty of Health Sciences,University of Macau,SAR,Taipa,Macao; 3.Department of Nephrology,Jiangnan University Medical Center,Wuxi,China; 4.Affiliated Wuxi Clinical College of Nantong University,Wuxi,China; 5.Department of Medicine and Therapeutics,The Chinese University of Hong Kong,Hong Kong; 6.State Key Laboratory of Digestive Disease,The Chinese University of Hong Kong,Hong Kong; 7.Department of Laboratory Medicine,the First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China; 8.Department of Pathology,the First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China; 9.Nordic Bioscience Biomarkers and Research A/S,Herlev,Denmark; 10.Fosun Diagnostics (Shanghai) Co.,Ltd,Shanghai,China; 11.MOE Frontier Science Centre for Precision Oncology,University of Macau,SAR,Taipa,Macao; 12.Southampton National Institute for Health and Care Research,Biomedical Research Centre,University of Southampton and University Hospital Southampton,Southampton,United Kingdom; 13.Department of Medicine,University of Verona,Verona,Italy; 14.IRCCS Sacro Cuore Don Calabria Hospital,Negrar di Valpolicella,Italy; 15.Storr Liver Centre,Westmead Institute for Medical Research,Westmead Hospital,Westmead,Australia; 16.University of Sydney,Sydney,Australia; 17.Institute of Hepatology,Wenzhou Medical University,Wenzhou,China; 18.Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province,Wenzhou,China
第一作者单位	附属第一医院
通讯作者单位	附属第一医院
第一作者的第一单位	附属第一医院
推荐引用方式 GB/T 7714	Tang, Liang-Jie,Sun, Dan-Qin,Song, Sherlot Juan,et al. Serum PRO-C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort[J]. LIVER INTERNATIONAL,2024,44(5):1129-1141.
APA	Tang, Liang-Jie., Sun, Dan-Qin., Song, Sherlot Juan., Yip, Terry Cheuk-Fung., Wong, Grace Lai-Hung., ... & Zheng, Ming-Hua. (2024). Serum PRO-C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort. LIVER INTERNATIONAL, 44(5), 1129-1141.
MLA	Tang, Liang-Jie,et al."Serum PRO-C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort".LIVER INTERNATIONAL 44.5(2024):1129-1141.